Journal of Cardiac Failure
Volume 12, Issue 7 , Pages 527-532 , September 2006

Significance of 8-Hydroxy-2′-Deoxyguanosine Levels in Patients With Idiopathic Dilated Cardiomyopathy

  • Eri Watanabe, MD

      Affiliations

    • From the Department of Cardiology, Aoyama Hospital, Tokyo Women's Medical University, Tokyo, Japan
    • Corresponding Author InformationReprint requests: Masatoshi Kawana, MD, Department of Cardiology, Aoyama Hospital, Tokyo Women's Medical University, 2-7-13 Kitaaoyama, Minatoku, Tokyo 107-0061, Japan.
    • ,
  • Naoki Matsuda, MD, PhD

      Affiliations

    • From the Department of Cardiology, Aoyama Hospital, Tokyo Women's Medical University, Tokyo, Japan
    • ,
  • Tsuyoshi Shiga, MD, PhD

      Affiliations

    • From the Department of Cardiology, Aoyama Hospital, Tokyo Women's Medical University, Tokyo, Japan
    • ,
  • Katsuya Kajimoto, MD, PhD

      Affiliations

    • From the Department of Cardiology, Aoyama Hospital, Tokyo Women's Medical University, Tokyo, Japan
    • ,
  • Yoichi Ajiro, MD, PhD

      Affiliations

    • From the Department of Cardiology, Aoyama Hospital, Tokyo Women's Medical University, Tokyo, Japan
    • ,
  • Hirotaka Kawarai, MD

      Affiliations

    • From the Department of Cardiology, Aoyama Hospital, Tokyo Women's Medical University, Tokyo, Japan
    • ,
  • Hiroshi Kasanuki, MD, PhD

      Affiliations

    • From the Department of Cardiology, Aoyama Hospital, Tokyo Women's Medical University, Tokyo, Japan
    • ,
  • Masatoshi Kawana, MD, PhD

      Affiliations

    • Department of Cardiology, Aoyama Hospital, Tokyo Women's Medical University, Tokyo, Japan

Received 25 January 2006 ,Revised 20 May 2006 ,Accepted 25 May 2006.

References 

  1. Dahlstrom U. Heart failure clinics: organization, development, and experiences. Curr Opin Cardiol. 2001;16:174–179
  2. Francis GS. Pathophysiology of chronic heart failure. Am J Med. 2001;110(Suppl 7A):37S–46S
  3. Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation. 1998;97:1536–1539
  4. Nakamura R, Egashira K, Machida Y, Hayashida S, Takeya M, Utsumi H, et al. Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation. Circulation. 2002;106:362–367
  5. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 1996;335:1182–1189
  6. Ungvari Z, Gupte SA, Recchia FA, Batkai S, Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol. 2005;3:221–229
  7. Pacher P, Schulz R, Liaudet L, Szabo C. Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci. 2005;26:302–310
  8. Yucel D, Aydogdu S, Cehreli S, Saydam G, Canatan H, Senes M, et al. Increased oxidative stress in dilated cardiomyopathic heart failure. Clin Chem. 1998;44:148–154
  9. Nordberg J, Arner ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med. 2001;31:1287–1312
  10. Makino Y, Okamoto K, Yoshikawa N, Aoshima M, Hirota K, Yodoi J, et al. Thioredoxin: a redox-regulating cellular cofactor for glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system. J Clin Invest. 1996;98:1469–1477
  11. Liu Y, Min W. Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ Res. 2002;90:1259–1266
  12. Bertini R, Howard OM, Dong HF, Oppenheim JJ, Bizzari C, Sergi R, et al. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J Exp Med. 1999;189:1783–1789
  13. Abdiu A, Nakamura H, Sahaf B, Yodoi J, Holmgren A, Rosen A. Thioredoxin blood level increases after severe burn injury. Antioxid Redox Signal. 2000;2:707–716
  14. Kishimoto C, Shioji K, Nakamura H, Nakayama Y, Yodoi J, Sasayama S. Serum thioredoxin (TRX) levels in patients with heart failure. Jpn Circ J. 2001;65:491–494
  15. Jekell A, Hossain A, Alehagen U, Dahlstrom U, Rosen A. Elevated circulating levels of thioredoxin and stress in chronic heart failure. Eur J Heart Fail. 2004;6:883–890
  16. Kasai H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2′-deoxyguanosisne, as a marker of cellular oxidative stress during carcinogenesis. Mutat Res. 1997;387:147–163
  17. Kaneko T, Tahara S, Matsuo M. Non-linear accumulation of 8-hydroxy-2′-deoxyguanosine, a marker of oxidized DNA damage, during aging. Mutat Res. 1996;316:277–285
  18. Ames BN. Endogenous oxidative DNA damage, aging, and cancer. Free Radical Res Commun. 1989;7:121–128
  19. Loft S, Vistisen K, Ewertz M, Tjonneland A, Overvad K, Poulsen HE. Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index. Carcinogenesis. 1992;13:2241–2247
  20. Leinonen J, Lehtimaki T, Toyokuni S, Okada K, Tanaka T, Hiai H, et al. New biomarker evidence of oxidative DNA damage in patients with non-insulin- dependent diabetes mellitus. FEBS Lett. 1997;409:150–152
  21. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology. Task force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841–842
  22. Toyokuni S, Tanaka T, Hattori Y, Nishiyama Y, Yoshida A, Uchida K, et al. Quantitative immunohistochemical determination of 8-hydroxy-2′-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate induced renal carcinogenesis model. Lab Invest. 1997;76:365–374
  23. Saito S, Yamauchi H, Hasui Y, Kurashige J, Ochi H, Yoshida K. Quantitive determination of urinary-8-hydroxydeoxyguanosine (8-OHdG) by using ELISA. Res Commun Mol Pathol Pharmacol. 2000;107:39–44
  24. Nakamura H, De Rosa S, Roederer M, Anderson MT, Dubs JG, Yodoi J, et al. Elevation of plasma thioredoxin levels in HIV-infected individuals. Int Immunol. 1996;8:603–611
  25. Nagaya N, Nishikimi T, Goto Y, Miyano Y, Kobayashi Y, Morii I, et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J. 1998;135:21–28
  26. Sorescu D, Griendling KK. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail. 2002;8:132–140
  27. Hamilton CA, Miller WH, Al-Benna S, Brosnan MJ, Drummond RD, McBride MW, et al. Strategies to reduce oxidative stress in cardiovascular disease. Clin Sci (Lond). 2004;106:219–234
  28. Moe G. Carvedilol in the treatment of chronic heart failure. Expert Opin Pharmacother. 2001;2:831–843

PII: S1071-9164(06)00274-0

doi: 10.1016/j.cardfail.2006.05.011

Journal of Cardiac Failure
Volume 12, Issue 7 , Pages 527-532 , September 2006

Article Tools

* Image Usage & Resolution